NASDAQ:AMED - Amedisys Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $289.00
  • Forecasted Upside: 9.47 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$264.00
▲ +5.73 (2.22%)

This chart shows the closing price for AMED by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amedisys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMED

Analyst Price Target is $289.00
▲ +9.47% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Amedisys in the last 3 months. The average price target is $289.00, with a high forecast of $350.00 and a low forecast of $245.00. The average price target represents a 9.47% upside from the last price of $264.00.

This chart shows the closing price for AMED for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 investment analysts is to buy stock in Amedisys. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/30/2021Royal Bank of CanadaBoost Price TargetOutperform$335.00 ➝ $350.00High
2/23/2021BenchmarkBoost Price TargetPositive ➝ Buy$275.00 ➝ $325.00Medium
2/8/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$275.00 ➝ $340.00Medium
1/5/2021TruistBoost Price Target$280.00 ➝ $325.00N/A
11/3/2020BarclaysBoost Price TargetOverweight$290.00 ➝ $298.00Medium
10/30/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$260.00 ➝ $275.00High
10/30/2020Credit Suisse GroupBoost Price TargetOutperform$246.00 ➝ $280.00High
9/21/2020OppenheimerBoost Price TargetOutperform$250.00 ➝ $260.00High
9/10/2020StephensReiterated RatingEqual Weight$235.00 ➝ $245.00Medium
9/2/2020BMO Capital MarketsBoost Price TargetMarket Perform$250.00 ➝ $270.00High
8/20/2020BarclaysInitiated CoverageOverweight$290.00 ➝ $290.00High
7/30/2020SunTrust BanksBoost Price TargetBuy$260.00 ➝ $270.00Medium
7/30/2020BenchmarkBoost Price TargetBuy$210.00 ➝ $250.00Medium
7/30/2020Royal Bank of CanadaBoost Price TargetOutperform$218.00 ➝ $260.00Medium
7/30/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$220.00 ➝ $260.00Medium
7/30/2020Raymond JamesBoost Price TargetOutperform$210.00 ➝ $255.00Medium
7/29/2020Jefferies Financial GroupBoost Price TargetBuy$225.00 ➝ $250.00Medium
7/10/2020SunTrust BanksBoost Price TargetBuy$240.00 ➝ $260.00Medium
6/18/2020BenchmarkUpgradeHold ➝ Buy$210.00High
5/21/2020SunTrust BanksBoost Price TargetBuy$225.00 ➝ $240.00High
5/11/2020UBS GroupLower Price TargetNeutral$208.00 ➝ $190.00Low
5/11/2020Raymond JamesLower Price TargetOutperform$225.00 ➝ $210.00Medium
5/10/2020Royal Bank of CanadaReiterated RatingBuy$218.00Medium
5/7/2020BenchmarkDowngradeBuy ➝ HoldHigh
4/27/2020OppenheimerReiterated RatingBuy$215.00Medium
3/9/2020BenchmarkUpgradeHold ➝ Buy$205.00High
2/21/2020StephensBoost Price TargetEqual Weight$180.00 ➝ $200.00Low
2/21/2020UBS GroupBoost Price TargetNeutral$154.00 ➝ $208.00Low
2/21/2020BMO Capital MarketsReiterated RatingMarket Perform$215.00Low
2/21/2020Credit Suisse GroupBoost Price TargetOutperform$206.00 ➝ $214.00Low
2/20/2020SunTrust BanksBoost Price TargetBuy$185.00 ➝ $225.00Low
2/20/2020Raymond JamesBoost Price TargetOutperform$200.00 ➝ $225.00Low
1/17/2020Credit Suisse GroupInitiated CoverageOutperform$206.00Low
1/3/2020Raymond JamesSet Price TargetOutperform$144.00 ➝ $200.00Medium
12/18/2019SunTrust BanksBoost Price TargetBuy$175.00 ➝ $185.00Low
12/6/2019BMO Capital MarketsInitiated CoverageMarket Perform$170.00Medium
11/26/2019Bank of AmericaBoost Price TargetBuy$170.00 ➝ $178.00Low
11/1/2019Robert W. BairdUpgradeNeutral ➝ Outperform$140.00 ➝ $160.00High
10/22/2019StephensReiterated RatingEqual Weight$145.00Low
10/21/2019StephensInitiated CoverageEqual Weight$145.00Low
9/16/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$155.00Low
8/5/2019BarclaysBoost Price TargetEqual Weight$120.00 ➝ $125.00High
8/2/2019Royal Bank of CanadaBoost Price TargetOutperform$150.00Low
8/1/2019OppenheimerBoost Price Target$140.00 ➝ $150.00Low
7/15/2019Raymond JamesBoost Price TargetOutperform$140.00 ➝ $144.00Medium
7/8/2019Jefferies Financial GroupSet Price TargetBuy$150.00Low
5/2/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$140.00High
3/21/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $120.00Low
3/1/2019Craig HallumLower Price TargetHold$132.00 ➝ $124.00Low
3/1/2019SunTrust BanksBoost Price TargetBuy$145.00Low
2/5/2019BenchmarkDowngradeBuy ➝ Hold$136.64High
12/14/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$130.00High
11/16/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$126.00Medium
10/30/2018BenchmarkUpgradeHold ➝ Buy$125.00High
10/26/2018Craig HallumDowngradeBuy ➝ Hold$116.00 ➝ $104.00Medium
10/11/2018Robert W. BairdBoost Price TargetNeutral$105.00 ➝ $120.00High
10/11/2018SunTrust BanksBoost Price TargetBuy$130.00High
10/11/2018Cantor FitzgeraldBoost Price TargetNeutral$117.00 ➝ $125.00High
9/18/2018Bank of AmericaSet Price TargetBuy$139.00Low
9/13/2018Cantor FitzgeraldInitiated CoverageNeutral$117.00Low
9/13/2018Canaccord GenuityInitiated CoverageNeutral$117.00Low
8/3/2018Royal Bank of CanadaBoost Price TargetOutperform$115.00Medium
7/3/2018Bank of AmericaUpgradeNeutral ➝ Buy$88.00 ➝ $97.00Medium
6/5/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$73.00 ➝ $78.00Medium
6/5/2018StephensReiterated RatingHold$78.00High
6/5/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$67.00 ➝ $72.00High
5/9/2018Craig HallumBoost Price TargetBuy$60.00 ➝ $82.00Low
5/8/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$66.00High
3/19/2018Royal Bank of CanadaUpgradeSector Perform ➝ OutperformLow
3/1/2018Robert W. BairdSet Price TargetNeutral ➝ Hold$60.00 ➝ $66.00Medium
3/1/2018OppenheimerBoost Price TargetOutperform$68.00 ➝ $63.00High
2/28/2018Jefferies Financial GroupSet Price TargetBuy$70.00Medium
11/21/2017William BlairReiterated RatingOutperformN/A
11/10/2017SunTrust BanksReiterated RatingBuy$70.00N/A
11/10/2017Robert W. BairdBoost Price TargetNeutral$50.00 ➝ $60.00N/A
11/9/2017Craig HallumReiterated RatingBuy$55.00 ➝ $68.00N/A
11/9/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$56.00 ➝ $62.00N/A
11/9/2017BenchmarkReiterated RatingBuy ➝ HoldN/A
11/8/2017MizuhoReiterated RatingBuy$55.00 ➝ $65.00N/A
11/2/2017BenchmarkUpgradeHold ➝ Buy$56.00N/A
11/2/2017MizuhoUpgradeNeutral ➝ Buy$55.00 ➝ $65.00N/A
10/23/2017Royal Bank of CanadaReiterated RatingHoldN/A
10/12/2017Jefferies Financial GroupReiterated RatingBuy$60.00N/A
10/9/2017SunTrust BanksReiterated RatingBuy$60.00N/A
10/4/2017Robert W. BairdReiterated RatingHold$50.00Low
9/15/2017OppenheimerReiterated RatingBuy$60.00Low
8/21/2017Bank of AmericaInitiated CoverageNeutral ➝ Neutral$55.00Low
7/26/2017MizuhoDowngradeBuy ➝ Neutral$50.00High
6/5/2017Royal Bank of CanadaReiterated RatingHold$56.00Low
5/4/2017StephensBoost Price TargetEqual Weight$50.00 ➝ $54.00Low
5/3/2017BenchmarkReiterated RatingHold ➝ Hold$50.00 ➝ $57.00High
5/3/2017MizuhoUpgradeNeutral ➝ Buy$65.00High
4/28/2017Jefferies Financial GroupReiterated RatingBuy$57.00Low
3/3/2017OppenheimerReiterated RatingOutperform$50.00 ➝ $59.00N/A
3/1/2017Jefferies Financial GroupBoost Price TargetBuy$50.00 ➝ $57.00N/A
3/1/2017MizuhoBoost Price TargetNeutral ➝ Neutral$33.00 ➝ $50.00N/A
1/27/2017BenchmarkInitiated CoverageHold$50.00N/A
1/17/2017Craig HallumSet Price TargetBuy$60.00N/A
1/13/2017Jefferies Financial GroupSet Price TargetBuy$50.00N/A
12/16/2016Craig HallumInitiated CoverageBuy$48.00N/A
11/9/2016MizuhoDowngradeBuy ➝ NeutralN/A
11/7/2016MizuhoUpgradeNeutral ➝ Buy$47.00N/A
11/4/2016MizuhoUpgradeNeutral ➝ Buy$47.00N/A
11/1/2016Jefferies Financial GroupReiterated RatingBuy$59.00 ➝ $50.00N/A
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/A
9/6/2016Jefferies Financial GroupReiterated RatingBuyN/A
8/3/2016MizuhoDowngradeBuy ➝ Neutral$57.00 ➝ $55.00N/A
(Data available from 7/25/2016 forward)
Amedisys logo
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. As of December 31, 2020, the company owned and operated 320 home health care centers, 180 hospice care centers, and 14 personal-care care centers in 39 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Read More

Today's Range

Now: $264.00
Low: $257.04
High: $265.01

50 Day Range

MA: $256.22
Low: $238.97
High: $270.32

52 Week Range

Now: $264.00
Low: $212.99
High: $325.12

Volume

186,819 shs

Average Volume

245,761 shs

Market Capitalization

$8.60 billion

P/E Ratio

43.56

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Amedisys?

The following Wall Street sell-side analysts have issued reports on Amedisys in the last year: Barclays PLC, Benchmark Co., BMO Capital Markets, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Stephens, SunTrust Banks, Inc., Truist, and Zacks Investment Research.
View the latest analyst ratings for AMED.

What is the current price target for Amedisys?

12 Wall Street analysts have set twelve-month price targets for Amedisys in the last year. Their average twelve-month price target is $289.00, suggesting a possible upside of 9.5%. Royal Bank of Canada has the highest price target set, predicting AMED will reach $350.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $245.00 for Amedisys in the next year.
View the latest price targets for AMED.

What is the current consensus analyst rating for Amedisys?

Amedisys currently has 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AMED will outperform the market and that investors should add to their positions of Amedisys.
View the latest ratings for AMED.

What other companies compete with Amedisys?

How do I contact Amedisys' investor relations team?

Amedisys' physical mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider's listed phone number is 225-292-2031 and its investor relations email address is [email protected] The official website for Amedisys is www.amedisys.com.